This Medscape CME activity is a general overview of clinical features, genetics, diagnosis and management of AATD.
Being sponsored by the makers of Prolastin, this otherwise excellent overview might be perceived as unbalanced due to commercial bias, since it failed to mention the recent Cochrane review which questioned the use of augmentation therapy. However, the omission may be more a matter of timing than commercial bias, since it was posted on Medscape very soon after the review came out and may have been in press before the review was released. That review has been criticized, and whether augmentation therapy should be abandoned is a matter of considerable controversy.
No comments:
Post a Comment